Literature DB >> 11847216

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.

Michael B Dilling1, Glen S Germain, Lorina Dudkin, Arun L Jayaraman, Xiongwen Zhang, Franklin C Harwood, Peter J Houghton.   

Abstract

To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosarcoma cells were selected for rapamycin resistance. Expression of c-Myc and anchorage-independent growth were enhanced in resistant cells. Resistance was unstable in each of three clones characterized. In resistant cells, as compared with parental cells, approximately 10-fold less 4E-binding protein (4E-BP) was bound to eIF4E, and total cellular 4E-BP was markedly reduced. Levels of eIF4E were unchanged. Steady-state levels of 4E-BP transcript remained unaltered, but the rate of 4E-BP synthesis was reduced in resistant cells. In cells that reverted to rapamycin sensitivity, levels of total 4E-BP returned to those of parental cells. Compared with parental cells, resistant clones had either similar or lower levels and activity of ribosomal p70 S6 kinase, but c-Myc levels were elevated in both resistant and revertant clones. Several colon carcinoma cell lines with intrinsic rapamycin resistance were found to have low 4E-BP:eIF4E ratios. In stable clones of HCT8 carcinoma engineered to overexpress 4E-BP, rapamycin sensitivity increased markedly (>1000-fold) as 4E-BP expression increased. These results suggest that the 4E-BP:eIF4E ratio is an important determinant of rapamycin resistance and controls certain aspects of the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847216     DOI: 10.1074/jbc.M110782200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Everolimus.

Authors:  Peter J Houghton
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 2.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Authors:  I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

3.  Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent.

Authors:  Suzan K Chao; Juan Lin; Jurriaan Brouwer-Visser; Amos B Smith; Susan Band Horwitz; Hayley M McDaid
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

4.  Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

Authors:  Ravi D Rao; Ann C Mladek; Jeffrey D Lamont; Jennie M Goble; Charles Erlichman; C David James; Jann N Sarkaria
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

5.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Matthew Spaits; Daniel J Noonan; Ekaterina Talovskaya; Andrew Eszterhas; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

Review 6.  Mechanisms of mTOR inhibitor resistance in cancer therapy.

Authors:  Jennifer S Carew; Kevin R Kelly; Steffan T Nawrocki
Journal:  Target Oncol       Date:  2011-03-09       Impact factor: 4.493

7.  Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.

Authors:  Peter J Houghton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Christopher L Morton; Stephen T Keir; C Patrick Reynolds; Min H Kang; Doris Phelps; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2011-02-18       Impact factor: 3.167

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

9.  Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.

Authors:  Xuerong Wang; Ping Yue; Young Ae Kim; Haian Fu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

10.  Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle.

Authors:  Caorui Lin; Gang Han; Hanhan Ning; Jun Song; Ning Ran; Xianfu Yi; Yiqi Seow; HaiFang Yin
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.